Skip to main content

Table 3 EGFR exon 19del subtypes in patients

From: Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

No. Subtypes Number of altered samples TKI response (total = 26)a
PR, N PD, N
1 c.2235_2249del
p.Glu746_Ala750del 20 10 2
2 c.2236_2250del
p.Glu746_Ala750del 13 7 1
3 c.2236_2248delinsAGCC
p.Glu746_Ala750delinsSerPro 1   1
4 c.2236_2252delinsCT
p.Glu746_Thr751delinsLeu 1   
5 c.2236_2257delinsCTCT
p.Glu746_Pro753delinsLeuSer 1   
6 c.2237_2252delinsT
p.Glu746_Thr751delinsVal 1   
7 c.2237_2255delinsT
p.Glu746_Ser752delinsVal 1 1  
8 c.2239_2247del
p.Leu747_Glu749del 1   
9 c.2239_2256del
p.Leu747_Ser752del 1   
10 c.2240_2254del
p.Leu747_Thr751del 2 1 1
11 c.2240_2257del
p.Leu747_Pro753delinsSer 5 2  
  1. apatients received the first-generation TKI treatment